{"id":"aflibercept-regeneron-usa","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Hypertension"},{"rate":"20-30","effect":"Proteinuria"},{"rate":"10-20","effect":"Hemorrhage"},{"rate":"5-10","effect":"Thromboembolic events"},{"rate":"1-2","effect":"Gastrointestinal perforation"},{"rate":"15-25","effect":"Fatigue"},{"rate":"20-30","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1742982","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aflibercept functions as a fusion protein combining VEGF-binding domains from VEGF receptors 1 and 2 with the Fc portion of human IgG1. By sequestering circulating VEGF and PlGF, it prevents these growth factors from activating their native receptors on endothelial cells, thereby suppressing new blood vessel formation and reducing pathological vascular leakage. This mechanism is particularly effective in conditions driven by excessive angiogenesis.","oneSentence":"Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting angiogenesis and vascular permeability.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:07.191Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (in combination with chemotherapy)"},{"name":"Wet age-related macular degeneration"},{"name":"Diabetic macular edema"},{"name":"Retinal vein occlusion"}]},"trialDetails":[{"nctId":"NCT05587062","phase":"PHASE3","title":"Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2019-10-01","conditions":"Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eylea®"],"phase":"phase_3","status":"active","brandName":"Aflibercept (Regeneron, USA)","genericName":"Aflibercept (Regeneron, USA)","companyName":"Cinnagen","companyId":"cinnagen","modality":"Biologic","firstApprovalDate":"","aiSummary":"Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting angiogenesis and vascular permeability. Used for Metastatic colorectal cancer (in combination with chemotherapy), Wet age-related macular degeneration, Diabetic macular edema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}